Hypera Pharma reports a BRL 242.2m net profit in 3Q18, a 46.1% increase over the same period last year
Hypera Pharma registra lucro líquido de BRL 242,2m no 3T18, um aumento de 46,1% em relação ao mesmo período do ano passado
Intel ID : 265995
|
||||
Relevant Documents
| Press Release | 26 Oct 2018 | Hypera_Press_Release_2018.pdf | PT |
|
| Intel ID | 265995 | |
| Value | EUR 57,79m | |
| Native Currency |
Brazilian Real (BRL)
Exchange Rate:  |
|
|
Financial Data - Hypera Pharma
(31 Dec 2024) |
Revenue: EUR 1.161,85m EBITDA: EUR 327,99m Net Debt: EUR 1.192,80m Exchange Rate:
|
|
| Date |
|
|
| Country |  |
|
| Region | ||
| Continent | |
|
| Geography | |
|
| Subsector (Old TTR Sectors) |
|
|
| Type |
|
|
| Intel Grade |
|
|
| Source |
|
|
| Tags | |
Target
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Secondary Sectors (TTRSC) |
30.01.01 Biopharmaceuticals 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals 30.01.04 Specialty Pharmaceuticals 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Legend:
Verified: Confirmed as a party to an active or possible transaction.
Potential: Unconfirmed as a party to an active or possible transaction.
Retained: Confirmed as “Retained” with a general or specific mandate.
Prospect: Advisory “Prospect” in discussions with or pitching services to possible client.
Transactional data is continuously updated by the research team and therefore is subject to change.